Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1
- Registration Number
- NCT02780700
- Locations
- 🇺🇸
Fort Wayne Medical Oncology Hematology, Fort Wayne, Indiana, United States
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Aromatase InhibitorDrug: Capecitabine
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 240
- Registration Number
- NCT02767661
- Locations
- 🇨🇳
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT02767752
- Locations
- 🇩🇰
Department of Oncology, Herlev, Denmark
Study of ONO-4538 in Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 680
- Registration Number
- NCT02746796
- Locations
- 🇯🇵
Tokyo Clinical Site2, Shinjuku-ku, Tokyo, Japan
🇨🇳Tainan Clinical Site1, Tainan, Taiwan
🇨🇳Tainan Clinical Site2, Tainan, Taiwan
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
- Conditions
- Oesophageal Cancer
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Lisette Nixon
- Target Recruit Count
- 584
- Registration Number
- NCT02741856
- Locations
- 🇬🇧
Bristol Haematology & Oncology, Bristol, United Kingdom
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇬🇧Velindre Cancer Care Centre, Cardiff, United Kingdom
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
- Conditions
- Gastro-entero-pancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- Target Recruit Count
- 35
- Registration Number
- NCT02736448
- Locations
- 🇮🇹
Irst Irccs, Meldola, FC, Italy
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 73
- Registration Number
- NCT02735239
- Locations
- 🇬🇧
Research Facility, Southampton, United Kingdom
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 29
- Registration Number
- NCT02734290
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT02726399
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- SecondaryCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 46
- Registration Number
- NCT02716766
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.